|Awarded On||August 16, 2017|
|Title||Targeting Therapy Resistance using Epithelial to Mesenchymal Transition (EMT) Pathways in Preclinical Claudin Low Breast Cancer Models|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Jeffrey M Rosen|
Targeted drug treatments have been used to treat some breast cancer subtypes, but there are no effective treatment options for patients with triple-negative breast cancer (TNBC). TNBC patients often tend to develop resistance to chemotherapy and metastasis. In fact, 1/3 of these TNBC patients live less than 3 years following diagnosis. It is now evident that breast cancer cells with stem cell properties are often present as a subpopulation of most breast cancers and are thought to be responsible for initiating tumor growth, resistance to chemotherapy as well as metastasis. Our laboratories have focused on understanding the properties and origins of these cells as well as defining the molecul...